6th international Symposium on Hepatitis Care in Substance Users Jersey City/New York, USA 6 - 8 September 2017

Invited Speakers

Brianna Norton
Dr. Brianna Norton is an assistant professor of medicine in the Divisions of General Internal Medicine and Infectious Diseases at Montefiore Medical Center/Albert Einstein College of Medicine. Her clinical work includes the treatment of HIV, Hepatitis C and opioid dependence in the primary care setting. She conducts research to improve linkage to HCV care and treatment for people who inject drugs. She is also the medical director of the NY Harm Reduction Educators, a syringe exchange program in East Harlem and the South Bronx.
Clifton Garmon
Clifton Garmon is a Senior Policy Analyst at VOCAL-NY where he monitors, examines, and promotes policies designed to improve the quality of life for marginalized communities, while engaging and educating elected officials across the state through grassroots lobbying. Clifton holds Bachelor degrees in Sociology and Political Science from Lenoir-Rhyne University, and a Masters in Social Work from Columbia University.
Dave Thomas
Dave Thomas is an Infectious Disease Specialist and Professor of Medicine at Johns Hopkins School of Medicine. His research and clinical interest is viral hepatitis, especially in HIV infected persons.
Elizabeth Owens
Elizabeth became a VOCAL-NY member in 2010 and was hired as a community organizer in 2012 to coordinate our GROW (Grassroots Organizing to Win) program for member-led base building and mobilization. She is a long-time community activist around LGBTQ and harm reduction issues and previously worked as a community outreach worker in the Bronx and Upper Manhattan.
Evaldo Stanislau
Infectious Disease doctor with more than 20 years in the field of viral hepatitis as a doctor and researcher, activist and stakeholder. Member of the Viral Hepatitis Scientific Advisory Board of Brazil MOH and WHO. Researcher on viral hepatitis at University of Sao Paulo. Former coordinator (and creator) of the Viral Hepatitis Program at the city of Sao Paulo. Senior advisor in charge of the implementation of interferon free therapy in Brazil by the MOH (2014-2015).
Hansel Tookes
Hansel Tookes, MD, MPH is Assistant Professor in the Department of Medicine at the University of Miami Miller School of Medicine. His research interests include behavioral interventions and innovative approaches to HIV prevention. While in Public Health School and Medical School, he authored 2 papers that were highly effective in advocating for the passage of the Infectious Disease Elimination Act, Miami’s Pilot Syringe Exchange Program. He is a member of the Board of Governors of the Florida Medical Association and has advocated successfully for health policy change in Tallahassee.
Holly Hagan
Holly Hagan, PhD, is an infectious disease epidemiologist, a Professor at New York University Meyers College and Co-Director of the NYU Center for Drug use and HIV Research. Her research has principally focused on the infectious disease consequences of substance use, and her main interest is in reducing the burden of hepatitis C virus (HCV) infection in people who inject drugs (PWID). Currently, she is leading a case-control study of the onset of injection among young people who use heroin or prescription painpills in rural New York state.
Jenifer Havens
Jennifer Havens, PhD, MPH trained in infectious diseases epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is currently an Associate Professor in the Center on Drug and Alcohol Research and Department of Behavioral Science at the University of Kentucky College of Medicine. Dr. Havens studies the epidemiology of prescription opioid abuse in rural Appalachia and has a keen interest in the infectious outcomes (HIV/hepatitis C) of injection drug use in this population. She has received three R01 awards from NIH/NIDA to research the rural opioid abuse/infectious disease syndemic.
Joan Duwve
Joan M. Duwve, MD, MPH is Associate Dean for Practice at the Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, and the Chief Medical Officer at the Indiana State Department of Health. She is the PI on a mixed methods study in Scott County and has co-authored multiple presentations and presented nationally on the HIV outbreak in Scott County and the opioid epidemic in Indiana. She co-chaired a statewide Prescription Drug Abuse Task Force, successfully championing legislation for evidence-based opioid prescribing, improved access to addiction treatment, and expanded access to/use of naloxone by first responders/lay savers.
John Ward
Dr. John Ward is Director of the Division of Viral Hepatitis at the CDC. During his tenure, Dr. Ward has guided development of national viral hepatitis surveillance, prevention research, policies and programs including those to promote education, vaccination, and testing with linkage to care and treatment. Dr. Ward initiated two Institute of Medicine (IOM) reviews of viral hepatitis prevention in the United States, and authored the first Action Plan for Viral Hepatitis Prevention, Care, and Treatment for the United States. Globally, Dr. Ward serves as an expert consultant to the World Health Organization, other international organizations and national ministries of health. Dr. Ward’s experience includes 14 years in the field of HIV/AIDS conducting early studies of HIV transmission, natural history and directing national HIV/AIDS surveillance. Dr. Ward has authored over 150 scientific publications, served as Editor of CDC’s Morbidity and Mortality Weekly Report (MMWR), and served as Editor for Silent Victories, a history of public health in the 20th century published in 2007 by Oxford University Press. Dr. Ward received his MD degree from the University of Alabama School of Medicine in Birmingham and completed an internship and residency in internal medicine at the University of Alabama Hospitals. He holds a clinical faculty appointment with the Department of Medicine, Emory University, Atlanta, GA.
Jordan Field
Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr. Feld is clinician-scientist based at the Toronto General Hospital, Toronto Centre for Liver Disease and the McLaughlin-Rotman Centre for Global Health.
Jorge Mera
Dr. Jorge Mera is the director of infectious diseases for Cherokee Nation Health Services (CNHS), the largest tribally operated health care system in the United States. During the last years his efforts have been dedicated to organizing the Cherokee Nation HCV elimination program as well as the HIV/HCV Extended Care Health Outcomes (ECHO) project in the tribe. He is also the Director of the HIV clinic since 2012 and the Director of the only Native American AETC local performance site in Oklahoma since 2013. Dr. Mera completed his fellowship in Infectious Diseases and Clinical Microbiology at Baylor College of Medicine in Houston, Texas and is Board Certified by the American Board of Internal Medicine (ABIM) in Infectious Diseases. He is a Clinical Assistant Professor in the Department of Internal Medicine of the Oklahoma State University Health Science Center and a Fellow of the American College of Physicians.
Judy Chang
Judy has worked in the HIV and community health and development field for eight years, across areas of programme management, resource mobilisation, and communications. She has been increasingly involved in harm reduction, community mobilisation and drug policy work, particularly in regards to women who use drugs. She has worked across India, China, and Thailand. She holds a Master’s in International Development and is an MPhil Candidate at the National Drug Research Institute, Australia.
Kevin Costello
Kevin Costello is the Litigation Director of the Center for Health Law and Policy Innovation. Prior to coming to CHLPI, Kevin was in private practice for eight years, most recently as a principal at Klein Kavanagh Costello, LLP. Kevin's practice involved complex litigation in the fields of housing, health care, civil rights, antitrust and consumer law. He has been appointed by federal courts across the country to represent classes in Multi-District Litigation, as well as in nationwide class action litigation. Kevin has brought lawsuits against major banks for broken promises arising from the federal government’s Home Affordable Modification Program, challenged the broadcast blackout restrictions of Major League Baseball and the National Hockey League and fought against the practices of law firms and banks in Massachusetts that improperly foreclosed on financially vulnerable homeowners. Kevin was also part of the team that litigated a series of cases uncovering systemic racial discrimination in the mortgage lending field. Prior to entering private practice, Kevin was a staff attorney at Community Legal Services in Philadelphia, helping seniors navigate the health care system. In this role, he fought to ensure that his low-income clients were treated fairly in the roll-out of the Medicare prescription drug benefit and litigated to enforce their rights in various public benefit and health care systems.
Mr. Costello is an honors graduate of both Boston College and the University of Pennsylvania Law School. He served as law clerk to both the Hon. Joseph H. Rodriguez of the U.S. District Court for the District of New Jersey and the Hon. Francis X. Spina of the Massachusetts Supreme Judicial Court.
Magdalena Harris
Magdalena Harris is an Associate Professor at the London School of Hygiene and Tropical Medicine where she conducts a programme of research investigating the lived experience of hepatitis C, its treatment and prevention in the UK. Magdalena also has experience of living with, and successfully undergoing treatment for hepatitis C.
Marina Klein
Dr. Marina Klein is Professor of Medicine, McGill University, Montreal, Canada in the Division of Infectious Diseases/Chronic Viral Illnesses where she is research director. Her clinical interests focus on treatment of patients with HIV and chronic viral hepatitis. She is a prominent researcher in clinical and epidemiologic aspects of HIV and Hepatitis C co-infection and leads a Canadian Institutes of Health Research (CIHR) funded prospective cohort study of over 1700 HIV-HCV co-infected patients to study the interaction of these chronic viral infections. She has also been a principal investigator in several clinical trials of HIV-HCV co-infection. Dr. Klein is also involved in a number of observational epidemiologic research collaborations (e.g. NA-ACCORD and CANOC) focused on understanding longterm clinical and treatment outcomes in HIV and in HIV-HCV co-infection where she has assumed a leadership role in scientific steering committees. She is currently serving as IAS Governing Council representative for the North American Region. In 2014 she assumed the role of National Co-Director of the CIHR-Canadian HIV Trials Network.
Mark Tyndall
Dr. Mark Tyndall is the Executive Medical Director of the BC Centre for Disease Control and Professor at the UBC School of Population and Public Health. He is an infectious diseases specialist with a focus on urban health and addiction. His career awards include the Michael Smith Foundation for Health Research Senior Scholar Award and the Ontario HIV Treatment Network Applied Research Chair. He is an author on over 250 peer-reviewed publications, with a focus on HIV and Hepatitis C care and prevention, harm reduction, and public health implementation research. He was co-lead investigator on the evaluation of Insite, North America’s first supervised injection site. Dr. Tyndall is a strong advocate and leader for public health in Canada and has fostered a number of community-based collaborations that have led to health policy changes.
Natasha Martin
Natasha K. Martin , DPhil, is an Associate Professor in the Division of Global Public Health in the Department of Medicine at the University of California San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Dr. Martin is an infectious disease and economic modeler. Dr. Martin’s work focuses on using dynamic epidemic modeling to evaluate the impact and cost-effectiveness of HIV, HCV, and HBV prevention interventions among high risk populations such as people who inject drugs, men who have sex with men, and incarcerated populations. She is one of the leading researchers examining the potential impact and cost-effectiveness of HCV treatment as prevention.
Norah Terrault
Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 275 original articles, reviews and book chapters. She has served as Associate Editor for Hepatology and Deputy Editor for Liver Transplantation in the recent past and is current Associate Editor for Hepatology Communications. She is an investigator on several NIH-funded clinical studies in hepatitis B and NASH and is an investigator on several ongoing clinical trials of therapies for patients with chronic hepatitis B, hepatitis C and NASH.
Ricardo Baptista Leite
Medical Doctor (ID-trained), Member of the Portuguese National Parliament and City Councilor of Cascais. President of ‘UNITE – Parliamentarians Network to End HIV/AIDS, Viral Hepatitis and Tuberculosis’. One of the six people to be awarded globally as a ‘HCV Change Maker’ by ‘The Economist’ in acknowledgment of leadership in the field of hepatatis c. Head of Public Health at Catolica University of Portugal and Coordinator of the Sustainable Healthcare Unit at NOVA Information Management School. PhD candidate at Maastricht University. Post-graduate studies at Johns Hopkins University, Harvard Kennedy School and Harvard Medical School. Founder of ‘CREATING HEALTH – Research and Innovation Funding’ and Co-founder of the ‘Estoril Conferences’. Main author of the book ‘Citizenship for Health’.
Rick Altice
Dr. Altice is a Professor of Medicine, Epidemiology and Public Health at Yale University where he serves as the Director of Clinical and Community Research, the Community Health Care Van and the HIV in Prisons Program. As a clinician, he is board-certified in both Infectious Diseases and Addiction Medicine. As a researcher, his interests are focused on the interface between infectious diseases, including HIV, tuberculosis, and viral hepatitis, and substance use disorders. Specifically, he is interested in both prevention and treatment issues and has been at the forefront of both behavioral and biomedical intervention research activities. He is also interested in creation of novel prevention and treatment programs for the treatment of HIV, viral hepatitis, tuberculosis, and substance use disorders in vulnerable populations, including people who inject drugs, criminal justice populations, men who have sex with men and both female and transgender sex workers. Dr. Altice has spent considerable time devoted to developing and studying integrated systems of care, including integrating medication-assisted therapies such as methadone, buprenorphine, and extended-release naltrexone into managing co-morbid conditions, including people living with or at risk for HIV, HCV, tuberculosis, and mental illness. In more recent years, given the many successful prevention and treatment interventions available, he has increasingly become involved in implementation science to find improved ways to disseminate research and evidence-based practices and ensure that they are implemented using best-practices.
Sarah Larney
Sarah Larney is a Senior Research Fellow at the National Drug and Alcohol Research Centre, University of New South Wales. Her work focuses on injecting drug use and related harms, including infectious diseases and intersections with the criminal justice system.
Stacey Trooskin
Stacey Trooskin, MD PhD, is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Health Centers. She received her MPH from Yale University School of Public Health, her medical degree from Robert Wood Johnson Medical School and her PhD from Rutgers School of Public Health. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania. Her primary research interest focuses on health disparities and developing and evaluating models of HCV care.
Slim Fourati
Slim Fourati is MD, PhD, is a reseacher in virology at University Paris-Est in Paris, France. He is also clinical virologist in the department of Microbiology, Henri Mondor Hospital, Creteil, France. He works in the research group of Pr Jean-Michel PAWLOTSKY to focus his research on HCV diagnosis, drug resistance and HBV pathogenesis and diagnosis
Tanya Applegate
Dr Tanya Applegate is a Senior Lecturer in the Viral Hepatitis and Clinical Research Program at the Kirby Institute, UNSW Australia and leads the Hepatitis C research laboratory team. Tanya currently leads the HCV research laboratory at The Kirby Institute, manages clinical samples from VHCRP-driven clinical trials/cohorts and facilitates all translational research conducted on these samples, including original research. Tanya has a strong interest in HCV translational research, focusing on the development and implementation of molecular diagnostics to improve HCV health care, particularly among marginalised populations and those living in lower and middle-income countries.